Pharmacist-guided genetic testing for antidepressant therapy
Pharmacist Guided Pre-emptive Pharmacogenetic Testing in Antidepressant Therapy
This study tests if using genetic testing to guide antidepressant treatment helps people with depression feel better compared to standard care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 190 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Basel Academic / other |
| Locations | 4 sites (Münchenbuchsee, Canton of Bern and 3 other locations) |
| Trial ID | NCT04507555 on ClinicalTrials.gov |
What this trial studies
This study at the Solothurn Psychiatric Clinic evaluates the effectiveness and tolerability of antidepressant medications by comparing a group receiving pharmacist-guided pharmacogenetic testing to a standard care group. In the intervention group, medication selection and dosing are tailored based on genetic testing results, while the standard group follows conventional practices without genetic input. Patients are monitored for progress after the first week of hospitalization, with random assignment to groups based on the need for medication adjustment. All medications used are approved for treating depression in Switzerland.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with moderate to severe unipolar depression or recurrent depressive disorder.
Not a fit: Patients with acute suicide risk, psychotic symptoms, or other serious psychiatric disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized antidepressant therapy for patients with depression.
How similar studies have performed: Other studies have shown promise in using pharmacogenetic testing to optimize antidepressant therapy, suggesting this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years old * Diagnosis unipolar moderate or severe depressive episode or recurrent depressive disorder (ICD10: F32.1/32.2/33.1/33.2) * HAM-D17 ≥ 17 Exclusion Criteria: * Acute suicide risk * Psychotic symptomatology * Other acute serious psychiatric disorder other than depression * Excessive consumption of alcohol and/or drugs * Severe acute - or severe chronic somatic diseases * Pregnant / lactating women * Under current treatment with fluoxetine
Where this trial is running
Münchenbuchsee, Canton of Bern and 3 other locations
- Privatklinik Wyss — Münchenbuchsee, Canton of Bern, Switzerland (Recruiting)
- Psychiatrische Dienste Solothurn — Solothurn, Canton of Solothurn, Switzerland (Recruiting)
- Luzerner Psychiatrie AG — Sankt Urban, Switzerland (Recruiting)
- Psychiatrische Universitätsklinik Zürich — Zurich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Thorsten Mikoteit, PD Dr. med. — Psychiatrische Dienste Solothurn
- Study coordinator: Céline Stäuble, MSc
- Email: celine.staeuble@unibas.ch
- Phone: +41 61 207 61 78
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.